Awesome Brother, True FDA Facts, No Hype, No Pump !!!
Regen BioPharma / BMSN HemaXellerate I™ Did Not Happen Over Night !!!
Regen BioPharma / BMSN Put Together A Team Of Experts To Submit
The Investigational New Drug (IND) Application to the FDA.
HemaXellerate I™ product is the only therapy that has potential to simultaneously block the underlying cause of aplastic anemia while at the same time rebuilding the bone marrow tissue that has been damaged by the disease."
If the clinical trial is successful, the company plans to expand use of HemaXellerate I™ to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market. This market is substantial in size and currently includes drugs such as Neupogen®, Neulasta®, Leukine® and Revolade®.
"Current drug-based approaches for healing bone marrow damage involve "flooding" the body with growth factors, which is extremely expensive and causes unintended consequences because of lack of selectivity," said Dr. Vladimir Bogin, CEO of Chromos Pharma (a contract research organization), which collaborated with Regen on filing the IND and member of the Company's Scientific Advisory Board. "Based on our data HemaXellerate I™ possesses the advantage delivering an optimized cellular mixture that produces the needed growth factors at the specific location in the bone marrow niche."
News 
Market Data 
Discover 
AI
